Personal Care Product Council

07/30/2025 | Press release | Archived content

PCPC Applauds Senate Health, Education, Labor, and Pensions Committee Passage on Reauthorization of the Over-the-Counter Monograph Drug User Fee Program

July 30, 2025

FOR IMMEDIATE RELEASE

CONTACTS:

Tesia Williams (202) 297-1232 [email protected]

Team [email protected]

PCPC Applauds Senate Health, Education, Labor, and Pensions Committee Passage on Reauthorization of the Over-the-Counter Monograph Drug User Fee Program

Washington, D.C.-"The Personal Care Products Council and our member companies applaud the Senate Health, Education, Labor, and Pensions (HELP) Committee on the passage of S.2292, the Over-the-Counter Monograph Drug User Fee Amendments Act. We thank Sens. Jim Banks (R-IN), Tim Kaine (D-VA), Jon Husted (R-OH), Andy Kim (D-NJ), Roger Marshall (R-KS) and Maggie Hassan (D-NH) for their leadership on the Over-the-Counter Monograph Drug User Fee Program (OMUFA) reauthorization. OMUFA has helped modernize the regulatory framework for over-the-counter products, like sunscreens, which are vital to consumer safety and well-being.

"We also commend the committee's commitment to advancing non-clinical testing methods, allowing FDA to consider a wider variety of evidence more attuned to the latest scientific advancements and global standards, and moving away from outdated and inhumane animal testing requirements. These critical improvements will accelerate U.S. consumers' access to the most advanced, effective and safest sunscreen UV filters and strengthen global competitiveness. We look forward to supporting enactment of these reforms as a part of the OMUFA reauthorization process."

###

Personal Care Product Council published this content on July 30, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on December 09, 2025 at 15:20 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]